Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sudden death prophylaxis in heart failure.

Salvatore Rosanio1, Ernst R Schwarz, Antonio Vitarelli

  • 1The Department of Internal Medicine, Division of Cardiology, The University of Texas Medical Branch, Galveston, Texas 77555-0553, United States. sarosani@utmb.edu

International Journal of Cardiology
|January 9, 2007
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-PCI Physiological Testing: Phenotyping Future Failure.

JACC. Cardiovascular interventions·2026
Same author

Preventing Parastomal Hernias After Radical Cystectomy with Ileal Conduit: A Systematic Review Regarding Surgical Prophylactic Techniques.

Journal of personalized medicine·2026
Same author

Platelet-rich plasma injections for the treatment of Peyronie's disease: a systematic review of contemporary literature with mixed-effects model analysis of penile curvature outcome.

Minerva urology and nephrology·2026
Same author

Effectiveness of hyaluronic acid in the treatment of Peyronie's disease in the light of the European Urology Guidelines: the real-world experience.

Minerva urology and nephrology·2025
Same author

ZEBRA: Z Stitch and Early Bedrest Study, a multicenter randomized clinical trial.

Heart rhythm·2025
Same author

Attempting to Define the Boundaries of Medical Futility in Contemporary Interventional Cardiology.

JACC. Cardiovascular interventions·2025

Sudden cardiac death (SCD) in heart failure (HF) is common. Implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) can prevent SCD, but better risk stratification is needed for optimal patient selection.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Sudden cardiac death (SCD) is the primary cause of mortality in patients with heart failure (HF).
  • Implantable cardioverter-defibrillators (ICDs) are widely used for SCD prevention in HF patients with low ejection fraction (EF), but EF alone is insufficient for risk stratification.
  • Left ventricular mechanical dyssynchrony is an emerging risk marker for cardiac mortality in HF.

Purpose of the Study:

  • To review the evidence for implantable ICDs and cardiac resynchronization therapy (CRT) in primary SCD prevention in HF.
  • To discuss controversial clinical aspects of device therapy in HF.
  • To recommend practical, evidence-based strategies for device management in HF patients.

Main Methods:

  • Systematic review of published evidence on ICDs and CRT for SCD prophylaxis in HF.

Related Experiment Videos

  • Analysis of clinical data and guidelines regarding risk stratification beyond ejection fraction.
  • Discussion of controversial issues and formulation of management recommendations.

    • Main Results:

    • Ejection fraction (EF) alone does not reliably differentiate between sudden arrhythmic death and non-sudden death in HF.
    • Electrophysiologic studies and microvolt T-wave alternans testing may improve risk stratification for ICD implantation.
    • Echocardiography for assessing left ventricular mechanical dyssynchrony is recommended over QRS duration measurement for CRT candidacy.

    Conclusions:

    • Optimizing patient selection for ICD and CRT is crucial to improve outcomes and minimize unnecessary device implants in HF.
    • Integrating assessment of mechanical dyssynchrony with SCD risk factors allows for better application of CRT and ICD therapies.
    • Further research and clinical consensus are needed to refine device-based management strategies for HF patients at risk of SCD.